Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 13:31:4.
doi: 10.18869/mjiri.31.4. eCollection 2017.

Cost-effectiveness of Eplerenone in treatment of cardiovascular diseases: a systematic review

Hossein Mobaraki  1 , Saber Azami-Aghdash  2 , Ali Sarabi Asiabar  2 , Aziz Rezapour  1 , Mohammad Hossein Kafaei Mehr  1 , Saeed Emamgolizadeh  3
Affiliations

Cost-effectiveness of Eplerenone in treatment of cardiovascular diseases: a systematic review

Hossein Mobaraki et al. Med J Islam Repub Iran. .

Abstract

Background: No clear evidence is available on the cost-effectiveness of eplerenone in treatment of cardiovascular diseases. Thus, the present study aimed at systematically reviewing studies that have investigated this issue. Methods: This systematic review study was conducted in 2016. The required information were collected using key Mesh words from the following databases: Google scholar, PubMed, Science Direct, MagIran, SID, Scopus, and handsearching journals and the references of the selected articles. The quality of the selected articles was assessed by the Drummond's checklist. Results: Nine articles were included from 296 articles found in the literature review. The selected studies have been conducted in 8 countries (The United States, Britain, Australia, Switzerland, France, Spain, the Netherlands, and Canada). In general, the costeffectiveness of eplerenone was investigated in 31 757 patients with cardiovascular diseases. The average of quality-adjusted life years (QALY) in studies with nonmodeling approach was equal to 0.0908 in Framingham approach, 0.0595 in Saskatchewan approach, and 0.1309 in Worcester approach. The overall average cost of treating cardiovascular diseases with eplerenone was equal to US$6694 in 1 year. Cost per additional (QALY) was estimated to be US$9478. Incremental cost-effectiveness ratio was high in the United States compared to European countries. The Average quality of articles was estimated to be 7.4 from 10. Conclusions: Based on the results of the studies reviewed in the present study, it seems that eplerenone has acceptable costeffectiveness compared with current treatments, placebo, and similar drugs.

Keywords: Cardiovascular Disease; Cost-effectiveness; Eplerenone; Systematic Review.

PubMed Disclaimer

Figures

Diagram. 1
Diagram. 1
Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
Fig. 4
Fig. 4
Fig. 5
Fig. 5
Fig. 6
Fig. 6
Fig. 7
Fig. 7
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Chung M, Asher R, Yamada D, Eagle K, Podrid P, Kowey P. Arrhythmias after cardiac and non-cardiac surgery In Cardiac arrhythmia 2nded Philadelphia. Lippincott Williams Wilkins. 2001:631–8.
    1. Yan JH, Pan L, Zhang XM, Sun CX, Cui GH. Lack of efficacy of Tai Chi in improving quality of life in breast cancer survivors: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3715–20. - PubMed
    1. Reinhardt UE, Cheng T-m. The world health report 2000-Health systems: improving performance. Bulletin of the World Health Organization. 2000;78(8):1064.
    1. Nagavi M. The pattern of mortality within 23 provinces of Iran in 2003, Tehran - IRAN: Health Deputy, Iranian Ministry of Health, 2005.
    1. Azami S, Tabrizi J, Abdollahi L, Yari Fard Kh, Daemi A, Sadati M. et al. Knowledge and Attitude of Top Managers toward Accreditation; in Tabriz and Ardabil Teaching Hospitals. Health. 2012;3(2):7–15.

LinkOut - more resources